Pay in 4 interest-free payments of $5.05 Learn more
Ships within 48 hours · Estimated delivery Oct 9 - Oct 14
Cardiovascular Risk Reduction Approval: Several GLP-1s have gained FDA approval for cardiovascular benefits, broadening their clinical utility
Obesity is often associated with erectile dysfunction, reduced testosterone levels in men, and decreased sexual satisfaction in both sexes
What tradeoffs matter for long-term health decisions
Compared with patients without diabetes, patients with diabetes have a 2fourfold higher risk of atherosclerotic cardiovascular diseases (ASCVD), including coronary artery disease, stroke, and peripheral artery disease [1]
The FDA has approved GLP-1 receptor agonists for type 2 diabetes management, with select agents (semaglutide/Wegovy and liraglutide/Saxenda) also approved for chronic weight management in adults with BMI 30 kg/m or 27 kg/m with at least one weight-related comorbidity
US$ 21.24
US$ 20.12
US$ 27.56
US$ 26.35
US$ 29.29
US$ 22.89
US$ 22.41
